SNAKEBITE
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Mission TherapeuticsUK - Cambridge
1 programWaveform Analysis In Snakebite Victims With HematotoxicityN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
OphirexVarespladib intravenous form
Mission TherapeuticsWaveform Analysis In Snakebite Victims With Hematotoxicity
Clinical Trials (2)
Total enrollment: 236 patients across 2 trials
Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)
Start: May 2023Est. completion: Feb 2025140 patients
Phase 2Completed
Waveform Analysis In Snakebite Victims With Hematotoxicity
Start: Mar 2022Est. completion: Jun 202396 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.